X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OPT-302 (sozinibercept) is a VEGF-C/D inhibitor, which is being evaluated in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD).
Lead Product(s): Sozinibercept,Aflibercept
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
The funding aims to support the OPT-302 (sozinibercept) in combination with ranibizumab, which is the first-in-class VEGF-C/D ‘trap’ in clinical development for Wet age-related macular degeneration.
Lead Product(s): Sozinibercept,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Carlyle Group
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 27, 2023
Details:
The company intends to use the net proceeds for advancing the Phase 3 clinical trials ShORe and COAST for OPT-302 (sozinibercept), a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D, for the treatment of wet AMD.
Lead Product(s): Sozinibercept,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $57.6 million Upfront Cash: Undisclosed
Deal Type: Financing August 28, 2023
Details:
OPT-302 (sozinibercept) is a novel recombinant trap fusion protein targeting inhibition of vascular endothelial growth factors C and D (VEGF-C and VEGF-C), two ligand mediators of angiogenesis and vascular leakage involved in retinal vascular diseases.
Lead Product(s): Sozinibercept,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
OPT-302, a VEGF-C/D inhibitor being investigated for neovascular age-related macular degeneration. It binds to and neutralizes the activity of VEGF-C and VEGF-D by preventing ligand binding to the endogenous receptors VEGFR-2 and VEGFR-3.
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Of the 366 participants dosed for OPT-302, 66 (18%) were identified as having PCV lesions at baseline based on multimodal imaging analysis of color fundus photography, fluorescein angiography and SD-OCT.
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
OPT-302 is a first-in-class VEGF-C/D inhibitor. It is a soluble fusion protein comprising immunoglobulin-like domains 1 to 3 of extracellular domain of vascular endothelial growth factor receptor 3 fused to Fc fragment of human IgG1.
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD).
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients.
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
The ShORe and COAST registrational studies are expected to each enroll approximately 990 treatment naïve patients and are evaluating OPT-302 combination therapy as a potential treatment for wet AMD.
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
